4.7 Review

Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome Opportunities for Improvement

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.05.030

关键词

adherence; ezetimibe; low-density lipoprotein cholesterol; secondary prevention; statin therapy

资金

  1. Amgen
  2. AstraZeneca
  3. Sanofi
  4. Aegerion
  5. Eli Lilly
  6. Genzyme
  7. GlaxoSmithKline
  8. Novartis
  9. Regeneron

向作者/读者索取更多资源

In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk. (C) 2015 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据